A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer

David C. Smith, Bruce G. Redman, Lawrence E. Flaherty, Lang LI, Myla Strawderman, Kenneth J. Pienta

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Objectives. To test the use of 1 mg/day of oral diethylstilbesterol (DES) as a treatment for patients with advanced prostate cancer who had failed primary hormonal therapy. Approximately 40,000 men this year will experience first-line hormonal therapy failure for their metastatic prostate cancer. At this time there is no standard therapy for men whose first-line hormonal manipulation has failed. This clinical problem has been exacerbated by the use of prostate-specific antigen (PSA) as a proved biomarker to follow disease progression. Patients who are experiencing hormonal therapy failure now present with a rising PSA, and virtually all are asymptomatic. The dilemma of how to treat these patients represents a new clinical problem for the medical oncologist and urologist that needs to be answered. Methods. We conducted a Phase II trial of oral DES in 21 patients. Patients were followed for response by PSA criteria and toxicity. A decrease in two serial measurements of PSA of greater than 50% from baseline was judged to be a partial response. Results. Nine of 21 patients achieved a PSA response (43% response rate with 95% confidence intervals of 22% to 64%) leading to early cessation of this Phase II trial. Eight of 13 patients (62%) who had only one prior hormone manipulation that failed demonstrated a PSA response, whereas only 1 of 8 patients (13%) who had received two or more hormone treatments responded (P = 0.07). The median follow-up is 82 weeks (range 8 to 122) among 16 surviving patients. The survival rate at 2 years is 63% (95% confidence interval 41% to 99%). Conclusions. DES appears to be an active agent for second-line hormone therapy for metastatic prostate cancer. Because it has been taken off the market for economic reasons, DES should be considered for development under the orphan drug strategy.

Original languageEnglish (US)
Pages (from-to)257-260
Number of pages4
JournalUrology
Volume52
Issue number2
DOIs
StatePublished - Aug 1998
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Hormones
Therapeutics
Orphan Drug Production
Confidence Intervals
Disease Progression
Survival Rate
Biomarkers
Economics

ASJC Scopus subject areas

  • Urology

Cite this

Smith, D. C., Redman, B. G., Flaherty, L. E., LI, L., Strawderman, M., & Pienta, K. J. (1998). A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology, 52(2), 257-260. https://doi.org/10.1016/S0090-4295(98)00173-3

A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. / Smith, David C.; Redman, Bruce G.; Flaherty, Lawrence E.; LI, Lang; Strawderman, Myla; Pienta, Kenneth J.

In: Urology, Vol. 52, No. 2, 08.1998, p. 257-260.

Research output: Contribution to journalArticle

Smith, DC, Redman, BG, Flaherty, LE, LI, L, Strawderman, M & Pienta, KJ 1998, 'A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer', Urology, vol. 52, no. 2, pp. 257-260. https://doi.org/10.1016/S0090-4295(98)00173-3
Smith, David C. ; Redman, Bruce G. ; Flaherty, Lawrence E. ; LI, Lang ; Strawderman, Myla ; Pienta, Kenneth J. / A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. In: Urology. 1998 ; Vol. 52, No. 2. pp. 257-260.
@article{1172af5b9915460b8e1dd4778d174a15,
title = "A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer",
abstract = "Objectives. To test the use of 1 mg/day of oral diethylstilbesterol (DES) as a treatment for patients with advanced prostate cancer who had failed primary hormonal therapy. Approximately 40,000 men this year will experience first-line hormonal therapy failure for their metastatic prostate cancer. At this time there is no standard therapy for men whose first-line hormonal manipulation has failed. This clinical problem has been exacerbated by the use of prostate-specific antigen (PSA) as a proved biomarker to follow disease progression. Patients who are experiencing hormonal therapy failure now present with a rising PSA, and virtually all are asymptomatic. The dilemma of how to treat these patients represents a new clinical problem for the medical oncologist and urologist that needs to be answered. Methods. We conducted a Phase II trial of oral DES in 21 patients. Patients were followed for response by PSA criteria and toxicity. A decrease in two serial measurements of PSA of greater than 50{\%} from baseline was judged to be a partial response. Results. Nine of 21 patients achieved a PSA response (43{\%} response rate with 95{\%} confidence intervals of 22{\%} to 64{\%}) leading to early cessation of this Phase II trial. Eight of 13 patients (62{\%}) who had only one prior hormone manipulation that failed demonstrated a PSA response, whereas only 1 of 8 patients (13{\%}) who had received two or more hormone treatments responded (P = 0.07). The median follow-up is 82 weeks (range 8 to 122) among 16 surviving patients. The survival rate at 2 years is 63{\%} (95{\%} confidence interval 41{\%} to 99{\%}). Conclusions. DES appears to be an active agent for second-line hormone therapy for metastatic prostate cancer. Because it has been taken off the market for economic reasons, DES should be considered for development under the orphan drug strategy.",
author = "Smith, {David C.} and Redman, {Bruce G.} and Flaherty, {Lawrence E.} and Lang LI and Myla Strawderman and Pienta, {Kenneth J.}",
year = "1998",
month = "8",
doi = "10.1016/S0090-4295(98)00173-3",
language = "English (US)",
volume = "52",
pages = "257--260",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer

AU - Smith, David C.

AU - Redman, Bruce G.

AU - Flaherty, Lawrence E.

AU - LI, Lang

AU - Strawderman, Myla

AU - Pienta, Kenneth J.

PY - 1998/8

Y1 - 1998/8

N2 - Objectives. To test the use of 1 mg/day of oral diethylstilbesterol (DES) as a treatment for patients with advanced prostate cancer who had failed primary hormonal therapy. Approximately 40,000 men this year will experience first-line hormonal therapy failure for their metastatic prostate cancer. At this time there is no standard therapy for men whose first-line hormonal manipulation has failed. This clinical problem has been exacerbated by the use of prostate-specific antigen (PSA) as a proved biomarker to follow disease progression. Patients who are experiencing hormonal therapy failure now present with a rising PSA, and virtually all are asymptomatic. The dilemma of how to treat these patients represents a new clinical problem for the medical oncologist and urologist that needs to be answered. Methods. We conducted a Phase II trial of oral DES in 21 patients. Patients were followed for response by PSA criteria and toxicity. A decrease in two serial measurements of PSA of greater than 50% from baseline was judged to be a partial response. Results. Nine of 21 patients achieved a PSA response (43% response rate with 95% confidence intervals of 22% to 64%) leading to early cessation of this Phase II trial. Eight of 13 patients (62%) who had only one prior hormone manipulation that failed demonstrated a PSA response, whereas only 1 of 8 patients (13%) who had received two or more hormone treatments responded (P = 0.07). The median follow-up is 82 weeks (range 8 to 122) among 16 surviving patients. The survival rate at 2 years is 63% (95% confidence interval 41% to 99%). Conclusions. DES appears to be an active agent for second-line hormone therapy for metastatic prostate cancer. Because it has been taken off the market for economic reasons, DES should be considered for development under the orphan drug strategy.

AB - Objectives. To test the use of 1 mg/day of oral diethylstilbesterol (DES) as a treatment for patients with advanced prostate cancer who had failed primary hormonal therapy. Approximately 40,000 men this year will experience first-line hormonal therapy failure for their metastatic prostate cancer. At this time there is no standard therapy for men whose first-line hormonal manipulation has failed. This clinical problem has been exacerbated by the use of prostate-specific antigen (PSA) as a proved biomarker to follow disease progression. Patients who are experiencing hormonal therapy failure now present with a rising PSA, and virtually all are asymptomatic. The dilemma of how to treat these patients represents a new clinical problem for the medical oncologist and urologist that needs to be answered. Methods. We conducted a Phase II trial of oral DES in 21 patients. Patients were followed for response by PSA criteria and toxicity. A decrease in two serial measurements of PSA of greater than 50% from baseline was judged to be a partial response. Results. Nine of 21 patients achieved a PSA response (43% response rate with 95% confidence intervals of 22% to 64%) leading to early cessation of this Phase II trial. Eight of 13 patients (62%) who had only one prior hormone manipulation that failed demonstrated a PSA response, whereas only 1 of 8 patients (13%) who had received two or more hormone treatments responded (P = 0.07). The median follow-up is 82 weeks (range 8 to 122) among 16 surviving patients. The survival rate at 2 years is 63% (95% confidence interval 41% to 99%). Conclusions. DES appears to be an active agent for second-line hormone therapy for metastatic prostate cancer. Because it has been taken off the market for economic reasons, DES should be considered for development under the orphan drug strategy.

UR - http://www.scopus.com/inward/record.url?scp=0032145396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032145396&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(98)00173-3

DO - 10.1016/S0090-4295(98)00173-3

M3 - Article

VL - 52

SP - 257

EP - 260

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -